Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Assets (2020 - 2025)

Foghorn Therapeutics has reported Other Non-Current Assets over the past 6 years, most recently at $4000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $4000.0 for Q4 2025, down 94.12% from a year ago — trailing twelve months through Dec 2025 was $4000.0 (down 94.12% YoY), and the annual figure for FY2025 was $4000.0, down 94.12%.
  • Other Non-Current Assets for Q4 2025 was $4000.0 at Foghorn Therapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for FHTX hit a ceiling of $2.4 million in Q4 2021 and a floor of $4000.0 in Q4 2025.
  • Median Other Non-Current Assets over the past 5 years was $1.7 million (2021), compared with a mean of $1.5 million.
  • Peak annual rise in Other Non-Current Assets hit 99.8% in 2025, while the deepest fall reached 94.12% in 2025.
  • Foghorn Therapeutics' Other Non-Current Assets stood at $2.4 million in 2021, then dropped by 0.88% to $2.4 million in 2022, then crashed by 53.13% to $1.1 million in 2023, then tumbled by 93.9% to $68000.0 in 2024, then tumbled by 94.12% to $4000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $4000.0 (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.